Dasatinib and Crizotinib in Advanced Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

March 31, 2019

Study Completion Date

March 31, 2019

Conditions
Advanced Cancers
Interventions
DRUG

Crizotinib

"Arm A Crizotinib dose: 250 mg by mouth twice a day in a 28 day cycle. Crizotinib Expansion dose: 250 mg by mouth twice a day in a 28 day cycle.~Arm B Crizotinib starting dose: 250 mg by mouth every other day in a 28 day cycle. Crizotinib Expansion Dose: MTD from dose escalation group."

DRUG

Dasatinib

"Arm A Dasatinib starting dose: 50 mg by mouth daily in a 28 day cycle. Arm A Dasatinib Expansion Dose: MTD from dose escalation group.~Arm B Dasatinib dose: 140 mg by mouth daily in a 28 day cycle. Arm B Dasatinib Expansion Dose: 140 mg by mouth daily in a 28 day cycle."

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER